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Flavone acetic acid induces a coagulopathy in mice
J.C. Murray, K.A. Smith & G. Thurston
CRC Gray Laboratory, PO Box 100, Mt Vernon Hospital, Northwood, Middlesex HA6 2JR, UK.
Summary The effects of flavone acetic acid (FAA) on the coagulation properties of plasma from tumour-
bearing and non-tumour-bearing mice have been investigated. The study was carried out primarily on CBA
mice and the CaNT tumour, although substantiating data are included for two other tumours grown in the
WH strain. FAA was injected at a range of single doses up to a maximum of 300 mgkg-', and clotting
properties of the plasma were measured in vitro at various times after FAA administration. Platelet numbers
and the concentration of fibrin degradation products (FDP) in the plasma were also determined. Following a
dose of 300 mg kg', the clotting times were significantly reduced at 15-30 min in both tumour-bearing and
non-tumour-bearing mice of both strains. Detailed studies on coagulation in the CBA strain (± CaNT tumour)
indicate that in tumour-bearing animals the initial decrease in clotting time is followed 4-6 h later by an
increase in clotting time, thrombin time and FDP levels. Platelet counts of tumour-bearing mice also decreased
signficantly over this period. Similar experiments in non-tumour-bearing mice did not show these late effects.
All the data from the coagulation tests on mice with CaNT tumours are consistent with the hypothesis that
intravascular coagulation occurs following treatment with FAA, and that vascular occlusion in tumours, as a
results of FAA-induced coagulopathy, may contribute to tumour regression.
Flavone acetic acid (FAA) is a synthetic flavonoid which is
currently undergoing clinical trials. Its clinical use is based on
its observed antitumour effects against a variety of solid
mouse tumours (Corbett et al., 1986; Bibby et al., 1987;
Finlay et al., 1988). However, unlike most antitumour agents
it is relatively non-toxic to cells in vitro (Bibby et al., 1987;
Capolongo et al., 1987; Schroyens et al., 1987), and conse-
quently its mechanism of action is uncertain. Several aspects
of the observed effects in tumours suggest that its toxicity in
vivo may be mediated via damage to the vasculature: (1) the
drug induces rapid cell death and tumour necrosis within
4-6 h (Smith et al., 1987; Finlay et al., 1988); (2) it is most
effective against solid tumours grown subcutaneously, show-
ing significantly less activity against lymphomas and leukae-
mias and tumours growing as ascites (Corbett et al., 1986;
Bibby et al., 1987); (3) it is more effective against large
established tumours than against newly implanted tumour
cells (Double et al., 1986; Finlay et al., 1988); (4) it causes a
rapid shutdown of tumour vasculature (Bibby et al., 1989;
Hill et al., 1989; Zwi et al., 1989).
Many of the features of FAA treated tumours have also
been observed in mice treated with tumour necrosis factor
(TNF) (Old, 1985), which suggests that common elements in
their mechanism of action may exist. Since TNF has been
shown to change the coagulant properties of endothelial cells
grown in vitro and to cause fibrin deposition in murine
tumours (Nawroth et al., 1988), we have investigated the role
of coagulation in the response of three murine tumours to
FAA. In this paper, we report the effects of single doses of
FAA on the clotting characteristics of plasma from tumour-
bearing and control mice.
Materials and methods
Mice and tumours
Experiments were carried out using three routinely passaged
tumours in use at the Gray Laboratory: CaNT, a moderately
differentiated adenocarcinoma, grown in CBA/HtBSVS mice,
and SaFA and FibT, two poorly differentiated fibrosarco-
mas, grown in WHT/GyBSVS mice. All experiments were
done using male mice. Tumours were implanted subcutan-
eously on the back as has been described previously (Smith et
al., 1988), and the animals were assayed when the tumours
were at a mean diameter of 10-12 mm.
Drugs and administration
FAA was generously provided by Lipha Pharmaceutical
(Lyon, France) and was resuspended in pure water to a stock
solution of 100 mg ml-'. Further dilutions were made up in
sterile saline. The drug was injected intra-peritoneally at an
appropriate concentration to allow a constant volume
(0.01 ml g') to be administered at each drug dose.
Plasma collection
In view of the difficulty of collecting large volumes of mouse
blood without initiating coagulation simply by the procedure
itself, a new method was developed. This method was used
for collecting all the samples except those needed for the
fibrin degradation product assay. Mice were anaesthetised
with methoxyflurane inhalation anaesthetic and then injected
intraveneously, via one of the lateral tail veins, with
400;LI 0.1M sodium citrate. The anti-coagulated blood was
collected by opening the chest under terminal anaesthesia
and cutting the aorta. The blood was immediately placed on
ice and centrifuged within 30 min at 1000 g for 10min. The
resulting platelet-poor plasma was then aliquoted and frozen
at - 20C. Each mouse yielded approximately 600 fli plasma,
and data points in each assay are the mean of 4-12 animals.
Assays
Platelet counts Platelet counts were obtained by adding
100 sl citrated whole blood to 200 l Isoton solution, and
counting with a Coulter Counter in the Department of
Haematology, Mount Vernon Hospital. The values obtained
were initially confirmed using a haemoyctometer.
The various clotting assays were performed on thawed
citrated plasma samples essentially as described in Dacie &
Lewis (1984). All tests were done at 37°C.
Clotting times The clotting time (CT) for each mouse was
measured by diluting 1001l1 plasma with 100 il PBS, adding
1001O.025M calcium chloride, and measuring the time till
formation of visible fibrin strands.
Prothrombin times For this assay, 100 yt plasma was com-
bined with 100 il rabbit brain thromboplastin (Manchester
Comparative Reagents, UK). One hundred ftl CaC12 was then
added, and the time to fibrin formation measured. The
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thromboplastin directly activates the extrinsic pathway and
consequently prothrombin times (PT) are shorter than for the
clotting time assay described above. Deficiencies in the ex-
trinsic pathway are indicated if the prothrombin times are
increased relative to control values.
Thrombin times One hundred p1l thrombin (concentration
approx. 100NIH units l1l 1) was added to 100 1I plasma
(diluted 1/10) and the time to clot formation again recorded.
Prolonged thrombin times usually indicate either a depletion
in plasma fibrinogen, or an increase in the concentration of
inhibitory fibrin degradation products.
Fibrin degradation product assay Fibrin degradation prod-
ucts (FDPs) in the plasma were detected using a Staphy-
locococal clumping assay (Sigma, UK) based on that des-
cribed by Hawiger et al. (1970). Blood was collected from the
thorax under terminal anaesthesia and immediately added to
vials containing an excess of thrombin. Under these condi-
tions, all the available fibrinogen is converted to fibrin and is
removed in clot formation. a- Aminocaproic acid was also
added to each vial to prevent further fibrinolysis. Serum
recovered after spinning the clotted sample was diluted to
give a range of plasma concentrations, and mixed with sta-
phylococcal cells suspensions. An estimate of the FDP level
in each sample was obtained by comparing the lowest serum
concentration at which clumping occured with the clumping
observed with samples of known fibrinogen concentration.
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Results
Platelet counts
Figure 1 shows the platelet counts obtained from untreated
mice and from mice given a single dose of 300 mg kg-' FAA
15-360 min earlier. Data are for non-tumour bearing CBA
mice and for mice with CaNT tumours with an average
measured diameter of 10-12 mm. In untreated mice, the
platelet counts from tumour-bearing mice were significantly
lower than those from CBA controls (P<0.01). Following
administration of FAA, the platelet counts from CBA mice
show only a small decrease over 6 h. By comparison, the
platelet counts from mice with CaNT tumours fall rapidly
from 30 min after injection of FAA, so that by 4 h after
injection the platelet counts have dropped by approximately
60%, indicating a significant FAA-induced thrombocyto-
penia.
The dose dependence of the effects of FAA on platelet
counts in tumour-bearing mice are shown in Figure 2. Data
are from the mice with 10-12 mm diameter CaNT tumours.
Blood samples were obtained 30 min and 360 min after injec-
tion. None of the FAA doses had an effect on the platelet
counts of samples collected 30 min after injection. However,
there is a dose-dependent decrease in the platelet counts of
mice treated 360 min earlier.
Clotting times
The clotting times of tumour-bearing and non-tumour-
bearing CBA mice following a dose of 300 mg kg-' FAA are
shown in Figure 3. Data are from 15 min to 6 h after injec-
tion. For mice given no FAA (i.e. at time 0), the samples of
plasma from mice with CaNT tumours had longer clotting
times than those from mice with no tumour (67±5 s vs
53±4s; P<0.01). Following FAA administration, the clot-
ting times of plasma from both groups decreased within
30 min of injection. In non-tumour mice, the clotting times
returned to normal within 60 min and were then stable over
the observation period. By comparison, the clotting times of
mice with 10-12 mm tumours remained depressed for app-
roximately 4 h after FAA injection, after which time an
increase was observed.
Similar changes in clotting time were observed following a
dose of 300 mgkg-' FAA in the WH mouse strain and in
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Figure 1 Platelet counts from blood samples obtained
30-360 min after 300 mgkg-' FAA. 0 times indicate values from
untreated animals. * CBA mice with 10-12 mm CaNT tumours;
* CBA mice. Data points are shown ± 1 s.e.m.
FAA dose (mg kg-1)
Figure 2 Platelet counts 30 min (-) and 360 min (0) after FAA
doses ranging from 0-300mgkg-' in CBA mice with 10-12mm
CaNT tumours. Data points are shown ± 1 s.e.m.
WH mice bearing FibT and SaFA tumours. As with the
CBA strain, the presence of a tumour also led to an increase
in the clotting times of untreated mice. The data from both
strains and all three types of tumour are summarised in
Table I. For each group, both the absolute values (in
seconds) and the percentage change in clotting time are
shown at 15-30 min and 4-6 h after injection.
Prothrombin times
The prothrombin times as a function of time after administ-
ration of 300 mg kg-' FAA are also shown in Figure 3. Data
are again from non-tumour-bearing CBA mice and mice with
10-12 mm CaNT tumours. The prothrombin times were
constant in both groups for at least 6 h after injection of
FAA.
The importance of thromboplastin on the differences
between the clotting and prothrombin times is shown in
Figure 4. Data in Figure 4a are from non-tumour bearing
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CBAs, and in Figure 4b from mice with CaNT tumours. In
both groups, FAA caused a reduction in clotting times.
However, these differences disappeared as the thromboplastin
concentration was increased. Both sets of data emphasise the
significant alteration in the coagulation potential of both
tumour-bearing and. control mice induced by FAA.
Experiments were also carried out to determine whether
FAA acts directly on coagulation factors in the blood. Blood
was collected as described previously, and samples of whole
blood or plasma incubated in vitro for 30 min at 37°C with
mg ml-' FAA. The samples were then processed as usual
and the clotting and prothrombin times measured. The
results showed that FAA added directly to blood or plasma
does not cause a decrease in clotting time similar to that
observed in vivo (data not shown).
Thrombin times
The thrombin times of both tumour bearing and non-tumour
bearing CBAs are plotted as a function of time after
300 mg kg-' FAA in Figure 5. For non-tumour bearing
animals, the thrombin times are constant for at least 6 h. By
comparison, although the thrombin times of tumour bearing
animals are constant for the first 4 h following FAA, a
significant increase in thrombin times is observed at 6 h
(from 18±0.8 at 4h to 30± 1.7 at 6h, P<0.05).
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Figure 4 Effect of thromboplastin concentration on clotting
times of mice with (a) and without (b) CaNT tumours. Filled
symbols, mice treated with 300 mg kg-' FAA 30 min earlier.
Open symbols, control mice.
FDP assay
FDP levels were measured in samples obtained I or 6 h after
300 mg kg-' FAA. Data from both non-tumour-bearing mice
and from mice with 10-12 mm tumours are plotted in Figure
6. In tumour-bearing mice, there was a dose-dependent inc-
rease in FDP levels I and 6 h after injection (Figure 6a). By
comparison, in non-tumour bearing mice there was no
significant change in FDP levels at any of the doses tested.
These results indicate a marked increase in fibrinolysis in
tumour-bearing mice treated with FAA even at early times
after treatment.
Table I Changes in simple clotting times after 300mg kg-' FAA
CBA WHT
No No
tumour CaNT tumour SaFa FibT
The change, and percentage change, (s) -13±3 -22± 3a 11±+4 -21± 7 -31+5 a
in clotting time 15-30min after (%) -25±6 -33±4 -22±8 -32±11 -43±lla
FAA treatment
The change, and percentage change, (s) 1±2 18±5a 1 ±4 17±11 -28± 6a
in clotting time 4-6 h after (%) 2±4 27± 7a 2±8 26±17 -39± 8a
FAA treatment
Mean values are shown ± 1 s.e.m. Each value is the mean from 4-12 animals. aSignificantly different
from untreated mice.
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coagulant activity is tollowed by a decrease in coagulation
potential suggesting a thrombotic episode.
The results of the clotting time (CT) assays indicate that
the coagulation pathway was activated in all mice after
administration of FAA, producing an early drop (within 1 h)
in CT. The absolute drop in CT was generally greater in
tumour-bearing mice, although the difference between
tumour-bearing and control mice did not achieve statistical
significance in our series of experiments (see Table I). FAA
did not influence the results obtained with the other coagula-
tion assays during this early phase. The mechanism by which
FAA initiates this early change in clotting potential in mice
has not been determined. However, we were unable to induce
a decrease in clotting time by adding FAA to citrated mouse
Time after FAA (min) plasma in vitro, which suggests that either the drug must be
converted to an active form in vivo or that the changes in 5 Thrombin times of mice 1 v360lmi after treatment coagulation are mediated via a cellular response.
s. * CBAs + 10- 12 mm CaNT tumours; m CBAs. Data During the period 4-6 h after injection of FAA, significant
are shown ± I s.d. differences in the clotting properties of non-tumour and tumour-bearing mice were observed. Clotting times (CT) in
tumour-bearing mice rose well above control values in two of
the three tumour systems tested (Table I). There was also
a significant depletion of platelets and fibrinogen and an inc-
rease in the levels of fibrin degradation products (FDP) in
the plasma. All these factors provide strong indirect evidence
that intravascular coagulation had occured in tumour-
bearing mice treated with FAA. The severity of these effects
was dependent upon the dose of FAA. We measured inc-
reases in the levels of FDP from 1 h after FAA administra-
tion, indicating that some degree ofclot formation and disso-
lution had occurred by that time. Significant depletion of
circulating fibrinogen was not observed until approximately-
6 h after drug administration, suggesting further coagulation
in tumour-bearing mice between 1 and 6h after FAA
administration.
An important feature of our studies was the observed
differences in the response ot tumour-bearing and non-
b tumour-bearing mice. The toxicity of FAA has also been
shown to be dependent on the presence of a tumour, with the
LD50 for tumour-bearing mice being approximately 40% of
the LDm in non-tumour-bearing mice (Hill et al., in prepara-
tion). It is possible that the greater toxicity of FAA to
tumour-bearing mice may be related to the changes in
coagulation reported here. Although FAA induced a reduc-
tion in the CTs of all treated mice within 30 min, the subse-
quent effects on coagulation in the animal appear to be
dependent on the presence of a tumour. This may be due to
systemic changes induced by the tumour. Conversely, in view
of the report that tumour cells can induce procogulant
activity on their associated endothelium (Nawroth et al.,
100 200 400 19), endothelnal cells in a tumour may be more susceptible
FAA dose (mg kg ') to the effects of FAA and form a focus for the initiation of
coagulation. Preliminary data from this laboratory for
6 Fibrin degradation product (FDP) levels in blood sam- clamped tumours treated with FAA indicate that the severity
om tumour bearing (a) and non-tumour bearing (b) mice. of the late changes in coagulation are reduced if blood flow
vere treated with FAA 30 min (open symbols) and 360 min to the tumour is occluded.
symbols) before sample collection. Data points are ± The experimental data reported here may have a direct
bearing on the observed clinical effects of FAA. In addition
to the observed hypotensive effect of FAA in patients, certain
bleeding disorders have been reported. Abnormal bleeding
times have been observed by investigators during phase 1
ion clinical trials (NCI report, NSC 347512, 1987), and Rubin et
al. (1987) reported changes in platelet aggregation and an
studies have shown that FAA causes a rapid and increase in bleeding times in some patients 24h after FAA.
nt decrease in tumour blood flow in experimental However, comparative data from non-tumour-bearers are not
s (Bibby et al., 1989; Hill et al., 1989; Zwi et al., available and it is impossible to know whether these effects
Further, Zwi et al. (1989) have produced in vivo/in are analogous to our observations in mice. The induction of
mour-cell survival data which indicate that cell death coagulation specifically within the tumour has been proposed
ie first 4 h post-FAA treatment may be due to as the mechanism by which endotoxin (Gratia & Linz, 1931)
ia resulting from the reduced blood flow. In this and TNF (Parr et al., 1973; Nawroth et al., 1988) exert their
paper we have sought to determine if the FAA antitumour action. Our own data also indicate that FAA
decrease in blood flow in tumours is due to altera- produces changes in coagulation, and in terms of the
coagulation, and have shown: (a) that FAA causes sequence of events taking place within 6 h of treatment, the
d procoagulant activity at short times after administ- effects of FAA in tumour-bearing mice fulfil many of the
(b) that in tumour-bearing mice, this increased pro- descriptive criteria of disseminated intravascular coagulation
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(DIC) (Brozovic, 1987). Although the results of our experi-
ments do not demonstrate a causal relationship between the
coagulopathy associated with single doses of FAA and
tumour regression, our data do indicate that FAA produces
changes in coagulation which in tumour-bearing mice leads
to a coagulopathy. We suggest that thrombus formation in
the tumour may cause the observed drop in tumour blood
flow following FAA administration, which then leads to
ischaemic cell death (Zwi et al., 1989). In order to ascertain
whether a causal relationship does exist between the observed
changes in coagulation and tumour regression, we are cur-
rently examining the effects of antithrombotic agents admini-
stered before FAA.
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